New Era: In the last decade, improvements in Cystic Fibrosis (CF) care have moved at a very welcome, yet rapid rate. The development of CF transmembrane conductance regulator (CFTR) modulator therapies and standardised multidisciplinary patient care have brought numerous benefits to people living with CF. Roll-out of the triple combination CFTR modulator compound, Kaftrio (Vertex pharmaceuticals), began in Ireland in September 2020.
Dubbed ‘wonder drugs’, many people with CF (pwCF) have benefited from these medications feeling less burden of disease and experiencing a new lease of life. Among the improvements are less frequent exacerbations, less hospital admissions, as well as new opportunities to travel, to work and to contemplate a future they hadn’t dared before.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
